Novartis: Fundamentals still there, momentum more questionableBUY, Fair Value CHF107 vs. CHF110 (+20%)
Nothing too serious or to be worried about but nothing to be excited about either in the Q3 numbers. This quarterly release leaves us with a mixed taste. Short term, RELAX HF2 is key. Without its support and although the current share price is attractive, we would not make Novartis a short-term BUY.
For more information, please contact firstname.lastname@example.org